Aduro Biotech Announces Collaboration With Johns Hopkins University to Evaluate Aduro Therapeutic Melanoma Vaccines in Combination With Anti-PD-1

Published: Apr 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduro’s vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants. The collaboration will be supported in part by a recent grant award from the Melanoma Research Foundation to Dr. Drake.

Help employers find you! Check out all the jobs and post your resume.

Back to news